(Reuters) - Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return ...

(Reuters) -Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tennessee last year spent $48 million on a single drug, Humira—about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So when ...

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought in ...

Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...

CVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie’s Humira from its list of covered drugs with cheaper alternatives for some customers—a move that’s ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Alternatives to the world’s ...